Chicago-based pharmaceutical company ResQ Pharma Inc announced on Monday that it has received a PDUFA (Prescription Drug User Fee Act) date of 2 June 2025, for its LipidRescue Kit.
If the kit receives approval, it will be used to treat Local Anesthetic Systemic Toxicity (LAST) with the rapid and accurate infusion of a clinically-recommended dose of lipid emulsion that has been shown to safely and effectively counteract toxicity and save patient lives. LAST is an uncommon but potentially fatal event that occurs during the use of local anaesthetics.
Dr Guy Weinberg, founder and president of ResQ Pharma and the inventor of LipidRescue Therapy (LRT), said: "Since discovering more than 25 years ago that lipid emulsion infusion could reverse catastrophic reactions to local anaesthetics, I have looked forward to the day that this novel therapy would become a widely available, standardised treatment for a dangerous and potentially fatal condition. As we await potential FDA review and approval, and prepare to launch the LipidRescue Kit, I'm very thankful to the many physicians, researchers, advisors and others who have been allies to ResQ Pharma over the years."
Scopio Labs secures fourth FDA clearance
Klotho Neurosciences receives FDA Orphan Drug Designation for ALS gene therapy candidate
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
Alvotech strengthens biosimilar operations with acquisition of Ivers-Lee Group
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Orsini named KalVista's specialty pharmacy partner for EKTERLY (sebetralstat)
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Biocon Biologics' Denosumab biosimilars receive European Commission approval
Life Molecular Imaging's Neuraceq granted expanded Alzheimer's disease indications by US FDA